Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports data showing Menveo to provide immunogenicity in infants

Novartis reports data showing Menveo to provide immunogenicity in infants

9th January 2008

Novartis has reported that new data shows its developmental vaccine Menveo to protect infants against four of the most common causes of meningococcal disease.

A recent study, published in the Journal of the American Medical Association, shows Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants.

The data also showed Menveo to be well-tolerated as well as generating high levels of immunogenicity in infants against meningococcal serogroups A, C, W-135 and Y.

Steve Black, adjunct professor of paediatric infectious diseases at Stanford University, welcomed the study and described the results as “encouraging”.

The results build on previous clinical trial findings which demonstrate strong immune responses in patients of all age groups when treated with Menveo.

“Novartis is making great progress toward our goal of protecting all age groups from all causes of meningococcal disease,” said Joerg Reinhardt, chief executive officer of Novartis Vaccines and Diagnostics.

The pharmaceutical company has confirmed that it expects to submit regulatory applications for Menveo in the European Union and the US this year.

Meanwhile, Novartis announced last month that Galvus, its new oral treatment for type two diabetes, had moved a step closer to widespread availability following positive feedback from EU health authorities.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.